Oncology News

Investigators developed a validated risk score to predict post-transplant survival for patients with hepatocellular carcinoma that will help prioritize patients based on predicted survival, according to study results.

Clinicians may be able to safely perform endoscopic biliary drainage for patients with hepatocellular carcinoma with jaundice and liver dysfunction with a high technical success rate, according to a study in BMC Gastroenterology.

Healio Gastroenterology presents the following reports on the most recent research in hepatology.

Patients with alcohol-related liver disease who survive for at least 1 year after diagnosis are at increased risk for cancer, according to study results.

Black patients with hepatocellular carcinoma have worse overall survival compared with white patients, according to study results.

Black patients with colorectal liver metastases had a lower likelihood of undergoing chemotherapy or resection and shorter survival than their counterparts of other races and ethnicities, according to a research letter in JAMA Network Open.

Compared with men, women had a significantly higher frequency of underlying nonalcoholic fatty liver disease and noncirrhotic hepatocellular carcinoma, according to data published in the American Journal of Gastroenterology.

Chronic liver diseases, including decompensated cirrhosis and hepatocellular carcinoma, were associated with increased mortality in patients with COVID-19, according to study results.

Among patients with hepatocellular carcinoma who first failed Retevmo, Stivarga and Opdivo provided similar outcomes in terms of survival as second-line treatments, according to research presented at The Digital International Liver Congress.

The combination of dabrafenib and trametinib appeared active among patients with BRAF V600E-mutated biliary tract cancer, according to results of an ongoing phase 2 basket trial published in The Lancet Oncology.